摘要
目的检测不同疾病类型心律失常患者心肌纤维化(MF)标志物血清水平,探讨其在不同疾病类型心律失常中的诊断价值。方法检测正常对照组和室性早搏、心房扑动、心房颤动、室性心动过速等不同类型心律失常疾病中转化生长因子β1(TGF-β1)、透明质酸(HA)、层粘连蛋白(LN)、Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原N端肽(PⅢNP)等MF标志物的血清水平,分析各指标在病例组和对照组及在不同疾病类型间的差异。结果病例组与对照组在HA、LN、PⅢNP水平上差异有统计学意义(P<0.05),且病例组血清水平高于正常组;在Ⅳ-C水平上两组差异无统计学意义(P>0.05)。在四类心律失常疾病患者中,TGF-β1、HA、LN、PⅢNP水平在不同的疾病类型中有着不同的分布差异,对疾病分类和鉴别诊断有一定的临床意义,其中室速患者的TGF-β1、HA和LN,房扑患者的Ⅳ-C,及室早患者的PⅢNP血清水平在四类疾病中是最高的。结论心律失常患者MF标志物的血清学水平在不同的疾病类型中有着不同的分布差异,对疾病分类和鉴别及是否需进行抗纤维化治疗有一定的临床意义。
Objective To detect the serum levels of myocardial fibrosis markers in patients with different types of arrhythmias,and explore their diagnostic value in these different types of diseases.Methods To measure the myocardial fibrosis makers levels of Transforming growth factor beta 1(TGF-β1),Hyaluronic acid(HA),Laminin(LN),Collagen Type IV(IV-C)and Collagen Type III N-terminal Peptide(P III NP)in normal control group and in different arrhythmias patients such as ventricular premature beat(VPB),atrial flutter,atrial fibrillation(AF)and ventricular tachycardia(VT),then to analyze their differences of the above markers between disease group and control group,and among the different diseases.Results There were statistical significantly differences between the case group and the control group in the levels of HA,LN and P III NP(P<0.05),and their levels in the case group were higher than the control group.While,the levels of collagen type IV there were no statistical significantly differences between the two group(P>0.05).In patients with the four arrhythmias,the levels of TGF-β1,HA,LN,P III NP had different distribution and had certain significance for classification and identification of the diseases.Among them,the levels of TGF-β1,HA,LN in ventricular tachycardia patients,the level of IV-C in atrial flutter patients and the level of PⅢNP in ventricular premature beat were the highest among the four diseases.Conclusion The serology levels of myocardial fibrosis makers in different arrhythmias patients have different distribution,which have a certain clinical significance for the diseases classification,identification and deciding whether have need for anti-fibrosis treatment.
作者
向丽
张维贞
黄山
田野
Xiang Li;Zhang Weizheng;Huang Shan;Tian Ye(Clinical Laboratory Medicine College,Guizhou Medical University.Guiyang 550002,Guizhou,China;Clinical Laboratory Center of Guizhou Provincial People's Hospital.Guiyang 550002,Guizhou,China;Department of Cardiology,Guizhou Provincial People's Hospital.Guiyang 550002,Guizhou,China)
出处
《贵州医药》
CAS
2019年第1期28-30,共3页
Guizhou Medical Journal
基金
贵州省科技厅社发公关项目[黔科合SY(2015)3045号]
